Press Releases Valneva SE Pref. Euronext Paris

Equities

VLAP

FR0011472943

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-7.89%	-28.57%

05-22	Valneva Se Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer	CI
05-21	Valneva Names New Chief Scientific Officer	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer	05-21	GL
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine	05-13	GL
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine	05-13	AQ
Valneva : Q1 2024 Financial Results	05-07	PU
Valneva : Reports First Quarter 2024 Financial Results and Provides Corporate Updates	05-07	PU
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates	05-07	GL
Valneva : Document AMF CP. 2024E960493	04-16	PU
World Vaccine Congress Washington: Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine in adults	04-04	PU
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	03-26	AQ
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	03-26	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	03-25	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	03-25	AQ
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	03-21	AQ
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.	03-21	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	03-20	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	03-20	AQ
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed	03-18	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	03-04	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	03-04	AQ
U.S. CDC Advisory Committee Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ	03-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Valneva SE Pref. Euronext Paris

Equities

VLAP

FR0011472943

Press Releases

Filters